McKinsey agrees to pay $574m to US states to settle opioid claimsBMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n360 (Published 08 February 2021) Cite this as: BMJ 2021;372:n360
- Owen Dyer
- Montreal, Canada
The consultancy firm McKinsey and Co will pay $574m (£420m; €480m) to resolve claims that it was a driving force behind many of the aggressive sales tactics used by US opioid manufacturers such as Purdue Pharma, the maker of OxyContin.1
The money will go to 47 states, five US territories, and the District of Columbia. Separate settlements will see McKinsey pay another $23m to Washington state and West Virginia. Only Nevada, where an investigation into opioid marketing continues, was not included in the package.
Purdue Pharma itself has agreed to pay $8.3bn in damages but has filed for bankruptcy, and states expect a long wait before they see any money. McKinsey, …